One hundred and twenty-five million women in malaria-endemic areas become pregnant
each year (see Dellicour et al. PLoS Med 7: e1000221 [2010]) and require protection from …

Malaria remains one of the most preventable causes of adverse birth outcomes. Intermittent
preventive treatment in pregnancy (IPTp) with sulfadoxine–pyrimethamine is used to prevent …

Background Intermittent treatment with sulfadoxine–pyrimethamine is widely recommended
for the prevention of malaria in pregnant women in Africa. However, with the spread of …

Background Every year, more than 32 million pregnancies in sub-Saharan Africa are at risk
of malaria infection and its adverse consequences. The effectiveness of the intermittent …

Background Intermittent treatment with sulfadoxine–pyrimethamine, recommended for
prevention of malaria in pregnant women throughout sub-Saharan Africa, is threatened by …

Background: Information regarding the safety and efficacy of artemisinin combination
treatments for malaria in pregnant women is limited, particularly among women who live in …

Objectives One of Africa's most important challenges is to improve maternal and neonatal
health. The identification of groups at highest risk for adverse pregnancy outcomes is …

Background The World Health Organization recommends intermittent preventive treatment
in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) in African regions with moderate …

Background Mefloquine is one of four antimalarial agents commonly recommended for
preventing malaria in travellers to malaria‐endemic areas. Despite its high efficacy, there is …

Pregnant women are especially susceptible to malaria infection. Without existing immunity,
severe malaria can develop requiring emergency treatment, and pregnancy loss is common …